Analysts Set Valneva SE Sponsored ADR (NASDAQ:VALN) Price Target at $11.98

Valneva SE Sponsored ADR (NASDAQ:VALN) has been assigned an average rating of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating and three have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.9750.

VALN has been the topic of a number of research reports. Guggenheim set a $11.00 price target on Valneva in a research report on Thursday, April 16th. Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, The Goldman Sachs Group cut Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price objective on the stock. in a research note on Wednesday, April 22nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Marex Group plc bought a new position in shares of Valneva during the second quarter valued at about $64,000. XTX Topco Ltd bought a new position in shares of Valneva during the fourth quarter valued at about $94,000. JPMorgan Chase & Co. bought a new position in shares of Valneva during the third quarter valued at about $124,000. VSM Wealth Advisory LLC grew its stake in shares of Valneva by 125.0% during the third quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Valneva during the fourth quarter valued at about $44,000. 11.39% of the stock is owned by institutional investors.

Valneva Trading Up 1.0%

NASDAQ VALN opened at $5.93 on Friday. The stock’s 50-day simple moving average is $6.57 and its two-hundred day simple moving average is $8.47. Valneva has a twelve month low of $5.06 and a twelve month high of $12.25. The company has a quick ratio of 1.60, a current ratio of 2.14 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $562.67 million, a price-to-earnings ratio of -3.17 and a beta of 1.72.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.42) earnings per share for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. The firm had revenue of $35.77 million for the quarter. Research analysts forecast that Valneva will post -1 EPS for the current fiscal year.

About Valneva

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.